Cytokinetics Inc. shares (NASDAQ:CYTK) rose $1.47, or 13.6 percent to close at $12.29 on Monday after, together with partner Amgen Inc., it shared new detail on the safety and benefits of omecamtiv mecarbil in patients with chronic heart failure (HF) during a presentation of phase II expansion phase data at the American Heart Association (AHA) Scientific Sessions.